Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials-Reference-Cited by-同舟云学术

Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials

Published:2013-09-10 Issue:7 Volume:109 Page:1717-1724
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Cesne A L,Judson I,Maki R,Grosso F,Schuetze S,Mehren M V,Chawla S P,Demetri G D,Nieto A,Tanovic A,Blay J-Y

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2013524.pdf

Reference29 articles.

1. Allavena P, Signorelli M, Chieppa M, Erba E, Bianchi G, Marchesi F, Olimpio CO, Bonardi C, Garbi A, Lissoni A, De Braud F, Jimeno J, D’Incalci M (2005) Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 65 (7): 2964–2971.

2. American Society of Clinical Oncology (ASCO) (1996) Update of recommendations for use of hematopoetic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 14 (6): 1957–1960.

3. Carter NJ, Keam SJ (2010) Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer. Drugs 70 (3): 355–376.

4. D'Incalci M, Galmarini CM (2010) A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 9 (8): 2157–2163.

5. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gomez J, Park YC, Le Cesne A (2009) Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 27 (25): 4188–4196.

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Geriatric Assessment of Older Patients Receiving Trabectedin in First-Line Treatment for Advanced Soft Tissue Sarcomas: The E-TRAB Study from The German Interdisciplinary Sarcoma Group (GISG-13);Cancers;2024-01-28

2. Hepatotoxicity of Anti-cancer Drugs;Interdisciplinary Cancer Research;2024

3. A review of the efficacy of trabectedin as second-line treatment of advanced soft tissue sarcoma;Future Oncology;2022-09

4. Trabectedin as second-line treatment in advanced soft tissue sarcoma: quality of life and safety outcomes;Future Oncology;2022-09

5. Trabectedin in Cancers: Mechanisms and Clinical Applications;Current Pharmaceutical Design;2022-07